Occurrence of second primary malignancy in medullary thyroid cancer (MTC) patients

446 Background: Renal cell carcinoma (RCC) survivors have an increased risk of developing second primary cancers. We sought to determine the role of RCC tumor histology for the risk of developing second primary solid tumors. Methods: The Surveillance Epidemiology and End Results (SEER) database was used to detect RCC cases diagnosed up to 12/31/2011. The Standardized Incidence Ratio (SIR) was calculated as the ratio of observed to expected cases of second primary malignancy based on incidence data in the general United States population. The two most common RCC histological subtypes were included; clear cell and papillary. The latency exclusion period from the date of diagnosis was 60 months. We investigated for the effect of latency period after initial diagnosis (5-10 years and >10 years) that may increase the risk for a second primary cancer. Results: A total of 2,669 patients with an initial diagnosis of RCC (clear cell: 2,368, papillary: 301) that developed second primary cancers were included in our analysis. There was a significantly increased risk of thyroid cancer (SIR: 2.30, p<0.05), prostate cancer (SIR: 1.12, p<0.05) and “all solid tumors” (SIR: 1.14, p<0.05) in clear cell RCC cases. Regarding latency period, thyroid cancer (SIR: 2.87, p<0.05) risk was increased in the 5-10 years latency period, but not in the >10 years latency period. Overall, in patients diagnosed with papillary RCC, tumors of the prostate (SIR: 1.30, p<0.05), lung (SIR: 1.78, p<0.05) and pancreas (SIR: 2.70, p<0.05) were increased. Exclusively in the 5-10 years latency period, the risk for developing lung cancer (SIR: 1.90, p<0.05) was significant. Conclusions: RCC histology may impact the risk for developing specific second primary solid tumors.

Download Full-text

Combination of medullary thyroid cancer and renal cell carcinoma in one patient

Clinical and experimental thyroidology ◽

10.14341/ket9259 ◽

2018 ◽

Vol 14 (1) ◽

pp. 34-38

Author(s):

Yuliya A. Dolinskaya ◽

Sergey P. Shevchenko ◽

Vladimir N. Maksimov ◽

Elena N. Voropaeva ◽

Oksana D. Rymar

Keyword(s):

Renal Cell Carcinoma ◽

Thyroid Cancer ◽

Cell Carcinoma ◽

Renal Cell ◽

Medullary Thyroid Cancer ◽

Malignant Neoplasm ◽

Later Life ◽

Second Primary ◽

Medullary Thyroid ◽

Increased Risk

Patients who received treatment for the first malignant neoplasm remain in the group at increased risk of developing a second primary tumor throughout their later life. A rare case of medullary thyroid cancer and renal cell carcinoma of the kidney is described in one patient. Medullary thyroid cancer is an orphan disease. The patient and his first-line relatives underwent molecular-genetic testing, the presence of a hereditary form of medullary cancer was excluded. During the observation, malignant kidney formation was detected, and surgical treatment was performed. The patient because of treatment and surveillance does not have data for the progression of thyroid cancer and kidney cancer, compensation for concomitant diseases has been achieved. When observing patients with medullary thyroid cancer, it is necessary to use the existing modern diagnostic arsenal, including positron emission tomography, since patients remain in the group at increased risk of disease progression and development of the second tumor throughout the entire subsequent life. In addition, this case clearly illustrates the need for a routine study of calcitonin as a diagnostic marker for the progression of medullary thyroid cancer.

Download Full-text

Thyroid carcinoma associated with other primary neoplasms, a single center study

Medicine and Pharmacy Reports ◽

10.15386/mpr-2346 ◽

2021 ◽

Author(s):

Katalin Gabora ◽

Ovidiu Bălăcescu ◽

Adrian Trifa ◽

Ana Maria Morariu ◽

Bogdan Pop ◽

...

Keyword(s):

Thyroid Cancer ◽

Thyroid Carcinoma ◽

Survival Rates ◽

Braf V600e Mutation ◽

Braf V600e ◽

Second Primary ◽

Time Interval ◽

Second Primary Malignancy ◽

Primary Malignancy ◽

Primary Neoplasms

Background and aims. Thyroid carcinoma is the most frequent endocrine malignancy. It develops following a complex interaction of environmental and genetic factors. Its incidence is on the rise mostly due to the frequent diagnosis of microcarcinomas (tumor<1 cm ). In most cases, it has very good prognosis and survival rates. The incidence of a second primary malignancy in thyroid cancer patients is higher than in the general population. In this article, we focus on the role of BRAF V600E mutation in the development of other primary neoplasms associated with thyroid carcinoma. Methods. This study was conducted in the department of Nuclear Medicine and Genetics of the "Prof. Dr. Ion Chiricuță” Institute of Oncology of Cluj-Napoca. We evaluated patients with thyroid carcinoma, who were diagnosed and treated for other malignancies such as breast, colorectal, lung cancer and malignant melanoma. In addition, we tested for the BRAF V600E mutation using paraffin samples of patients. Results. We identified 17 patients that had thyroid carcinoma associated with other primary malignancies. Two of the patients included in the study had three associated primary cancers. The time interval between the diagnoses of two primary neoplasms in the same patient was 6.15 years, with a standard deviation (SD) of 5.39 years. The most common primary tumor associated with thyroid carcinoma in this study was breast cancer. We applied genetic testing for the BRAF V600E mutation in 12 patients. The BRAF V600E mutation positivity rate was 26.9% and most of the cancer associations were metachronous (occurring at least 6 months after thyroid cancer). Conclusions. The BRAF V600E mutation is an important prognostic factor in the neoplasms included in this study, but its presence is not a predictive factor for the appearance of a metachronous or synchronous associated primary neoplasm to thyroid cancer.

Download Full-text

The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative131I dose over 37 GBq

Clinical Endocrinology ◽

10.1111/cen.12581 ◽

2014 ◽

Vol 83 (1) ◽

pp. 117-123 ◽

Cited By ~ 11

Author(s):

Ah Reum Khang ◽

Sun Wook Cho ◽

Hoon Sung Choi ◽

Hwa Young Ahn ◽

Won Sang Yoo ◽

...

Keyword(s):

Thyroid Cancer ◽

Cancer Patients ◽

Differentiated Thyroid Cancer ◽

Second Primary ◽

Second Primary Malignancy ◽

Primary Malignancy

Download Full-text

Incidence of Second Malignancy in Patients with Papillary Thyroid Cancer from Surveillance, Epidemiology, and End Results 13 Dataset

Journal of Thyroid Research ◽

10.1155/2018/8765369 ◽

2018 ◽

Vol 2018 ◽

pp. 1-11 ◽

Cited By ~ 6

Author(s):

Mayumi Endo ◽

Jessica B. Liu ◽

Marcelle Dougan ◽

Jennifer S. Lee

Keyword(s):

Thyroid Cancer ◽

Papillary Thyroid Cancer ◽

Incidence Rates ◽

Lymphocytic Leukemia ◽

Second Primary ◽

Papillary Thyroid ◽

Second Primary Malignancy ◽

Primary Malignancy ◽

Increased Risk ◽

End Results

Increased risk of second primary malignancy (SPM) in papillary thyroid cancer (PTC) has been reported. Here, we present the most updated incidence rates of second primary malignancy from original diagnosis of PTC by using the data from the Surveillance, Epidemiology, and End Results. In this cohort, 3,200 patients developed SPM, a substantially higher number than in the reference population of 2,749 with observed to expected ratio (O/E) of 1.16 (95% CI; 1.12–1.21). Bone and joint cancer had the highest O/E ratio of 4.26 (95% confidence interval [CI] 2.33–7.15) followed by salivary gland (O/E 4.15; 95% CI 2.76–6.0) and acute lymphocytic leukemia (O/E 3.98; 95% CI 2.12–6.8). Mean age at the diagnosis of SPM was 64.4 years old. Interestingly, incidence of colorectal cancer was lower in thyroid cancer survivors compared to general population (large intestine O/E 0.3; 95% CI 0.06–0.88, rectum O/E 0.6; 95% CI 0.41–0.85); however, this was not observed in patients who underwent radiation therapy. The incidence of SPM at all sites was higher during 2000–2012 compared to 1992–1999 (O/E 1.24 versus 1.10). Surprisingly, patients with micropapillary cancer had higher incidence of SPM than counterparts with a larger tumor in radiation group (O/E of 1.40 versus 1.15). O/E of all cancers were higher in males compared to females with O/E of 1.41 versus 1.17 during the period of 2000–2012. Diagnosis of PTC before age 50, especially at age 30–34, was associated with higher incidence of overall SPM (age 30–34; O/E 1.43; 95% CI; 1.19–1.71). Efficient monitoring strategies that include age at the time of thyroid cancer diagnosis, exposure to radiation, gender, and genetic susceptibility may successfully detect SPM earlier in the disease course. This is especially important given the excellent prognosis of the initial thyroid cancer itself.

Download Full-text